Meditrina Pharmaceuticals has announced the approval of its second investigational new drug application for a Phase IIb dose ranging clinical trial to study MPI-676, the company's aromatase inhibitor, in combination with estrogen and progestin for the treatment of endometriosis.

Meditrina Pharmaceuticals has completed a global licensing agreement to make, develop and commercialize products under AstraZeneca's intelectual property and know-how regarding the use of aromatase inhibitors in combination with estrogen and progestin to treat endometriosis.